CGRP mAb Subcutaneous denied as non-formulary by UnitedHealthcare?

UnitedHealthcare's specific coverage criteria for cgrp mab subcutaneous are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why UnitedHealthcare Denies CGRP Monoclonal Antibodies as Non-Formulary

UnitedHealthcare structures its drug formulary in tiers, and subcutaneous CGRP monoclonal antibodies are frequently placed on specialty tiers or excluded from certain plan formularies altogether. A non-formulary denial means the plan's pharmacy benefit does not include the specific agent prescribed, or that the agent is on a tier with cost-sharing your plan does not cover. This is distinct from a medical-necessity denial: UHC is not saying the drug is inappropriate, only that it is not on the approved drug list for your specific benefit design.

## Why This Denial Is Appealable

Non-formulary denials are still adverse benefit determinations and carry the same appeal rights as medical-necessity denials. Under ACA §2719, you have access to an internal appeal and, if unsuccessful, an independent external review. For ERISA-governed employer plans, ERISA §503 guarantees a full-and-fair review. The external-review window is typically 4 months from a final internal denial. An expedited pathway is available for urgent clinical situations.

Critically, insurers are required to grant a formulary exception when no formulary alternative is clinically appropriate for a specific patient. This is the core legal theory of a non-formulary appeal.

## The Appeal Process

1. Obtain UHC's formulary exception request procedure — this is often a faster parallel track alongside a formal appeal. 2. File a written internal appeal citing the formulary-exception standard: that formulary alternatives are contraindicated, have failed, or are otherwise clinically inappropriate for this patient. 3. If the internal appeal is denied, escalate to external review through UHC's assigned Independent Review Organization within the window stated on the denial letter.

## Documentation to Gather

• Formulary-alternative trial history: Dated records showing every formulary-listed preventive agent tried, including duration, dosing changes, and why each was inadequate.
• Clinical differentiation: Prescriber's explanation of why the specific non-formulary agent is necessary and why listed alternatives cannot be substituted.
• Diagnosis and severity records: Specialist notes confirming migraine diagnosis, frequency, and functional burden.
• Formulary exception letter: A focused letter from the prescriber stating the clinical rationale for exception in language that directly matches UHC's exception criteria.

## Criteria-Mapping Structure

Review UHC's published formulary exception policy. List each condition for granting an exception. For each condition, cite the specific chart entry, note date, or test result that satisfies it. Keep the response tightly organized so the reviewer can find the answer to every criterion without searching.